Investment Rating - Buy (maintained) [2] Core Views - Revenue slightly contracted, but the amount of winning bids increased significantly [2] - The company is a leader in urban rail transit design consulting and will benefit from the development of urban rail transit [2] - The company's gross profit margin increased, and financial expenses decreased [2] - The company's winning bid amount for the first half of 2024 was RMB 5.793 billion, a year-on-year increase of 91.19% [2] - The company's design, survey, and consulting business segment achieved a gross profit margin of 30.03%, an increase of 1.33 percentage points year-on-year [2] Financial Performance - Revenue for the first half of 2024 was RMB 4.18 billion, a year-on-year decrease of 6.95% [2] - Net profit for the first half of 2024 was RMB 377 million, a year-on-year decrease of 5.75% [2] - Comprehensive gross profit margin was 19.67%, an increase of 0.84 percentage points year-on-year [2] - Operating cash flow was -RMB 721 million due to lower operating receipts than payments [2] - Financial expenses were RMB 141 million, a year-on-year decrease of 4.08% [2] Business Segments - Design, survey, and consulting business segment revenue was RMB 2.021 billion, a year-on-year decrease of 10.34% [2] - Urban rail transit engineering segment revenue was RMB 1.521 billion, a year-on-year decrease of 3.73% [2] - Industrial and civil construction and municipal engineering segment revenue was RMB 500 million, a year-on-year decrease of 25.82% [2] - Engineering contracting business segment revenue was RMB 2.159 billion, a year-on-year decrease of 3.57% [2] - Gross profit margin for this segment was 9.96%, an increase of 1.03 percentage points year-on-year [2] Winning Bids - Total winning bids for the first half of 2024 were RMB 5.793 billion, a year-on-year increase of 91.19% [2] - Design, survey, and consulting winning bids were RMB 1.784 billion [2] - Engineering contracting winning bids were RMB 4.009 billion [2] - The company won 4 design projects for urban rail transit in Beijing and Shenzhen, solidifying its leading position in the industry [2] - The company secured a single project worth over RMB 1 billion in ecological environment management [2] Financial Forecast - Expected net profit attributable to the parent company for 2024-2026 is RMB 941 million, RMB 1.072 billion, and RMB 1.118 billion, respectively [2] - Expected EPS for 2024-2026 is RMB 0.70, RMB 0.79, and RMB 0.83, respectively [2] - Current P/E ratios for 2024-2026 are 2.0x, 1.7x, and 1.6x, respectively [2] Market Data - Current stock price: HKD 1.500 [4] - Total market capitalization: HKD 2.023 billion [4] - Free float market capitalization: HKD 582 million [4] - Total shares outstanding: 1.349 billion [4] - Free float shares: 388 million [4] - 3-month turnover rate: 9.49% [4]

证券研究报告 | 2024年09月03日 康诺亚-B（02162.HK） 优于大市 临床开发快速推进，商业化准备积极进行 司普奇拜单抗临床开发快速推进，积极为商业化做准备。康诺亚的核心产品 IL4R 单抗司普奇拜单抗（CM310）治疗成人中重度特应性皮炎（AD）的上市 申请于 23 年 12 月获药监局受理并纳入优先审评，有望在 24 年下半年获批， 成为首个获批上市的国产 IL4R 单抗。并且，司普奇拜单抗读出了成人 AD 优 秀的长期随访数据。CRSwNP、过敏性鼻炎适应症的上市申请也已经获得 CDE 受理。其他适应症中，青少年 AD、结节性痒疹等的 3 期临床正在进行中。司 普奇拜单抗开发进度领先，覆盖人群广泛，有望成为自免领域的重磅产品。 截至 2024 年 7 月，公司商业化团队已接近 200 人规模，积极为司普奇拜单 抗的商业化进行前期准备。 管线布局丰富，临床推进顺利。公司的 CLDN18.2 ADC（CMG901）早期临床数 据优秀，合作伙伴阿斯利康已开启针对 2/3L 胃癌的全球多中心 3 期临床， 并在胰腺癌、胃癌等实体瘤中进行联合用药的 2 期临床探索。CM313（CD38 单抗）在 I ...

证券研究报告 | 半年报点评 gszqdatemark 2024 09 03 年 月 日 科济药业-B（02171.HK） 赛恺泽商业化推进顺利，同种异体 CAR-T 进入临床研究 科济药业发布 2024 年中期业绩。公司 2024 上半年实现收入 6 百万元，净亏损 为 3.52 亿元，2023 年同期为亏损 4.04 亿元；实现经调整净亏损 3.42 亿元，2023 年同期为亏损 3.86 亿元。 科济药业宣布舒瑞基奥仑塞注射液中国确证性 2 期临床完成入组。该临床试验 旨在评价舒瑞基奥仑赛注射液治疗 Claudin18.2 表达阳性、既往接受过至少 2 种治 疗失败的晚期胃癌╱食管胃结合部腺癌的患者的有效性和安全性。 观点：赛恺泽商业化推进顺利，同种异体 CAR-T 进入临床研究。 收入端为人民币 6 百万元，主要来自赛恺泽®（（泽基基奥仑赛注射液，自体 BCMA CAR-T 细胞产品）。赛恺泽®的主要收入是以出厂价格进行计算而非终端市场价计 算，收益于完成产品出厂交付后确认；此外从华东医药获得里程碑付款人民币 75 百万元。利润端亏损收窄，除获得产品收入外研发开支同比减少。 主要产品推进情况： ➢ 赛 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HK$61.98, reflecting a potential upside of 42% from the current price of HK$43.50 [2][4][8]. Core Insights - The company is expected to achieve a revenue CAGR of approximately 30% from 2024 to 2026, driven by strong market demand for its products [2][3]. - The company reported a significant increase in product revenue for 1H24, reaching RMB 3.81 billion, a year-on-year growth of 55.1% [2][6]. - The gross margin for 1H24 was 84.1%, an increase of 1.8 percentage points compared to the previous year, attributed to rising sales and decreasing production costs [2][3]. - The company has multiple key products in the cardiovascular and metabolic (CVM) fields awaiting approval, which are considered crucial for future growth [2][3]. Financial Summary - The company's revenue is projected to grow from RMB 6,206 million in 2023 to RMB 12,948 million by 2026, with a gross profit increasing from RMB 5,070 million to RMB 10,667 million over the same period [1][12]. - The net profit is expected to turn positive by 2025, reaching RMB 1,004 million, and further increasing to RMB 2,508 million by 2026 [1][12]. - The earnings per share (EPS) is forecasted to improve from a loss of RMB 0.66 in 2023 to a profit of RMB 1.61 by 2026 [1][12]. Valuation Analysis - The report employs a two-stage DCF valuation method, resulting in a target price of HK$61.98, which corresponds to a 2025 enterprise value/revenue multiple of 7.7x, significantly higher than the comparable company average of 4.0x [8][9]. - The WACC used in the valuation is 10.2%, with a perpetual growth rate of 3% [8][9].

Investment Rating - The report assigns a **Buy** rating to Shenwei Pharmaceutical (2877 HK) with a target price of HK$18.00, representing a 106% upside potential from the current price of HK$8.75 [1][2] Core Views - Shenwei Pharmaceutical's exclusive products are growing steadily, and traditional Chinese medicine (TCM) formula granules are expected to recover growth after 2H24 [3] - The company's revenue and net profit are forecasted to grow at a CAGR of 11% and 10% respectively from 2023 to 2026 [3] - The target price is based on a DCF model with a WACC of 12.1% and a perpetual growth rate of 0.5%, implying a 2025E P/E of 11x, in line with the industry average [14] Financial Performance - In 1H24, Shenwei Pharmaceutical reported revenue of RMB 2.087 billion, down 13% YoY, while net profit grew 28% YoY to RMB 626 million [4] - Excluding one-time items, adjusted net profit declined 5% YoY to RMB 409 million [4] - Gross margin improved slightly by 0.1 ppts to 75.3% in 1H24 [4] - Free cash flow was RMB 489 million in 1H24, with an interim dividend of RMB 83 million and a trailing 12-month dividend yield of 40% [4] - Net cash per share stood at HK$7.64, representing 87% of the latest closing price [4] Product Performance - Injection sales declined 19% YoY to RMB 779 million in 1H24, with the flagship product Qingkailing down 9% YoY to RMB 366 million [4] - Soft capsule sales fell 18% YoY to RMB 289 million, while granule sales grew 4% YoY to RMB 345 million, driven by a 12% increase in Huamoyan granules [4] - TCM formula granule sales dropped 12% YoY to RMB 555 million in 1H24, with sales in Hebei and Yunnan hospitals down 1% YoY, accounting for 90.4% of total formula granule revenue [5] Forecast Adjustments - Revenue forecasts for 2024-26 were lowered by 5%/8%/8%, mainly due to weaker-than-expected injection and formula granule sales [11] - Gross profit forecasts for 2024-26 were revised down by 5%/8%/9%, while net profit and EPS forecasts were cut by 5%/8%/8% [13] - Injection revenue forecasts for 2024-26 were reduced by 8%/12%/13%, and formula granule revenue forecasts were lowered by 9%/13%/16% [12] Valuation - The DCF target price of HK$18.00 implies a 2025E P/E of 11x, in line with the industry average of 10x [14] - Shenwei Pharmaceutical trades at a discount to A-share peers, with a 2025E P/E of 6x vs. the A-share average of 20x [19]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 132.37 HKD, based on a projected adjusted PE of 12x for 2024, corresponding to a market capitalization of 338.7 billion CNY [2][8]. Core Insights - The company reported Q2 2024 revenue of 33.93 billion CNY, slightly below Bloomberg consensus of 34.11 billion CNY, with an adjusted net profit of 7.40 billion CNY, exceeding the consensus estimate of 6.68 billion CNY [1]. - Core advertising remains under pressure, while cloud business shows strong growth. The core revenue was 26.69 billion CNY, up 1.1% year-over-year, with advertising revenue at 19.2 billion CNY, down 2.0% year-over-year, which was better than the expected decline of 2.9% [1]. - Cost control is excellent, with a core gross margin of 59.2% and an operating profit margin (OPM) of 21.0%, which is above market expectations [1]. - AI large models are restructuring the company's business, with significant increases in user engagement and application. The daily invocation of the Wenxin large model has exceeded 600 million times, and nearly 18% of search results are generated by AI [1]. - The autonomous driving service "Luobo Kuaipao" saw a 26% year-over-year increase in order volume, reaching approximately 899,000 orders in Q2 2024 [1]. Financial Summary - The company expects adjusted net profits of 27.4 billion CNY, 29.2 billion CNY, and 30.3 billion CNY for 2024, 2025, and 2026 respectively, with revenue projections of 135 billion CNY, 142.9 billion CNY, and 151.6 billion CNY for the same years [2][8]. - The report outlines a forecast for core revenue growth, with online marketing expected to decline slightly in the near term, while cloud services are projected to grow significantly [7].

证 券 研 究 报 告 众安在线（06060.HK）深度研究报告 推荐（维持） 基本盘稳定，业务边界不断拓展 目标价：15.1 港元 互联网保险第一股，互联网+保险基因构筑核心竞争力。众安在线是中国首家 互联网保险公司，以"保险+科技"作为其核心战略，通过旗下子公司在保险、 科技、虚拟银行等业务领域实现多元化布局。从股东阵营、高管配置来看，众 安具备在互联网+保险行业精细化运营的基础，已具备一定的先发优势。 看点一：发力互联网非车险业务，看好其持续领先地位。2022 年上半年，公 司在互联网财险市场中以 20%的市场份额排名行业第二，保持领先地位。相较 于其他大型财险公司（平安财险、人保财险、太保财险），众安由于战略及险 种结构的差异，赔付率持续低于行业，费用率虽然高于其他大型财险公司，但 随着自营渠道建设效果显现+科技助力，预计 COR 或将持续改善。众安主营 互联网财险业务，并主要聚焦于非车险业务。互联网车险业务规模增长与渗透 率提升整体受限，而互联网非车险拥有场景化、生态化的属性，渠道以第三方 为主，是众安的优势所在。 看点二：借力银行与科技板块打造第二增长曲线，有望逐步实现盈亏平衡。 2023 年，公 ...

Investment Rating - The report maintains a "Buy" rating for Meituan (3690 HK) with a target price of HK$193.00, representing an upside potential of 88% from the current price of HK$102.80 [2][5][12]. Core Insights - The report highlights strong growth in key segments, with a significant increase in order volume for the in-store, hotel, and travel business, which saw a year-on-year growth of 60% in Q2 2024. The operating profit margin is expected to improve to 34% due to stabilizing industry competition [6][11]. - The report also notes that the on-demand delivery segment, which includes food delivery and flash purchase, experienced a 14.2% year-on-year increase in order volume in Q2 2024, with total revenue growth estimated at 17% [11][30]. - The report projects that the core local business operating profit will grow by 28% year-on-year in 2024, up from a previous estimate of 16%, driven by improved profitability in food delivery, flash purchase, and in-store services [12][30]. Summary by Sections Financial Performance - Revenue for 2024 is projected at RMB 334,451 million, reflecting a 19% year-on-year growth, with adjusted EBITDA expected to reach RMB 44,161 million, a 24% increase [15][26]. - The adjusted net income for 2024 is forecasted at RMB 41,503 million, representing a 13% increase from previous estimates [15][26]. Segment Analysis - The in-store, hotel, and travel segment is expected to generate RMB 57,050 million in revenue for 2024, with a year-on-year growth of 25% [26][68]. - The on-demand delivery segment is projected to achieve a revenue growth of 18.7% in 2024, with a significant improvement in profitability due to reduced subsidies and enhanced operational efficiency [11][30]. Valuation - The report employs a sum-of-the-parts (SOTP) valuation approach, assigning a 15x P/E multiple to the food delivery business, resulting in a valuation of USD 65 billion, and a 0.8x P/GMV multiple for community e-commerce, leading to a valuation of USD 52 billion [17][19][30]. - The overall SOTP valuation for Meituan is estimated at HK$1,230 billion, supporting the target price of HK$193 [32].

1H24 运营稳健、新院扩张有序落地，未来股份回购加速，下调目标价 1H24 整体经营稳健，业务量强劲增长：1H24 公司收入和经调整净利润分 别同比增长 35.4%/15.5%，利润增速低于管理层此前的全年指引，主要受 到医保坏账以及其他一次性损益的影响；剔除该影响后的经营收入、经营 毛利和经调整经营净利润分别增长 37.6%/39.4%/38.2%，得益于原有医院 稳健增长、新收购长安和宜兴医院的贡献以及利润率改善。门诊服务和住 院服务收入分别增长 49.6%/31.3%；肿瘤业务增长 31%，在总收入中占 44%，与 2023 全年水平基本持平。顺应医保支付改革大趋势，公司提升高 定价项目服务能力，1H24 手术量和手术收入分别增长 29%/39%。此外， 公司不断拓展创新模式，并已在永鼎、长安、单县、重庆医院开展互联网 医院服务，1H24 互联网医院挂号数量接近 10 万人次。 新增产能有序落地，未来更多资金用于回购：拥有 1,000 张床位的德州海 吉亚医院已正式投用，无锡（800-1,000 张）和常熟（800-1,200 张）海吉 亚有望于明年交付使用；广济二期、长安三期、永鼎二期已启动筹备，开 ...

Investment Rating - The report maintains a "Buy" rating for Miniso Group (9896.HK) [2] Core Views - The company's revenue for the first half of 2024 reached 77.59 billion RMB, a year-on-year increase of 25.0%, with adjusted net profit at 12.42 billion RMB, up 17.8% [1] - The company continues to expand its store network, aiming to open 900-1100 new stores globally in 2024, with a total of 6,868 stores as of June 30, 2024 [1] - The report highlights strong performance in overseas markets, with revenue growth of 42.6% year-on-year in the first half of 2024 [1] Summary by Sections Financial Performance - For 24H1, the company achieved a revenue of 77.59 billion RMB, with a domestic revenue of 50.27 billion RMB (up 17.2%) and overseas revenue of 27.32 billion RMB (up 42.6%) [1] - Adjusted net profit margin for 24H1 was 16.2%, reflecting a stable profitability despite increased costs due to store expansion [1] Store Expansion - As of June 30, 2024, the company had opened 6,868 stores, with 4,115 in China and 2,753 overseas, marking an increase of 1,077 stores year-on-year [1] - The company plans to add 340-450 domestic stores and 550-650 overseas stores in 2024, with progress at 42%-54% for domestic and 41%-48% for overseas as of mid-2024 [1] Future Projections - The report forecasts adjusted net profits of 28.28 billion RMB, 34.87 billion RMB, and 41.67 billion RMB for the years 2024, 2025, and 2026, respectively, with corresponding year-on-year growth rates of 20.0%, 23.3%, and 19.5% [1] - The projected P/E ratios for 2024, 2025, and 2026 are 14X, 11X, and 10X, respectively [1]